These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25297456)

  • 1. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
    Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
    Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.
    Suri A; Pusalkar S; Li Y; Prakash S
    Clin Pharmacol Drug Dev; 2016 May; 5(3):180-7. PubMed ID: 27163496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.
    Kumar A; S VK; Gurav S; Zainuddin M; Dewang P; Kethiri RR; Rajagopal S; Mullangi R
    Biomed Chromatogr; 2013 Dec; 27(12):1590-4. PubMed ID: 23788266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
    Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.
    Suri A; Pham T; MacLean DB
    Clin Pharmacol Drug Dev; 2016 May; 5(3):188-95. PubMed ID: 27163497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals.
    Goto A; Moriya Y; Takeuchi T; Mandai T; Tagawa Y; Kondo T; Asahi S
    Drug Res (Stuttg); 2016 Apr; 66(4):217-22. PubMed ID: 26418412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
    Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
    Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orteronel for the treatment of prostate cancer.
    Van Hook K; Huang T; Alumkal JJ
    Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
    Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
    Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM; Rogers SA; Aubé J; Scott EE
    Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
    Roviello G; Pacifico C; Chiriacò G; Generali D
    Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.